Shares of Exact Sciences (NASDAQ: EXAS) surged again on Thursday as investors continued to react to reports that Abbott Laboratories (NYSE: ABT) is nearing a potential acquisition of the cancer-diagnostics company.
The stock jumped sharply intraday, extending Wednesday’s rally and signaling strong market conviction around a possible deal.
EXAS Stock Jumps Nearly 20% Today
Exact Sciences continued its momentum today, trading up almost 20% as of the latest session.
The stock climbed from an opening price near the high-$60s to intraday highs above $88, reflecting strong investor optimism. Trading volume was significantly elevated, suggesting heavy institutional activity.
This price action follows Wednesday’s breakout, when EXAS initially surged more than 25% after news broke of advanced takeover discussions.
Abbott Shares Dip as Market Weighs Deal Costs
In contrast, Abbott Laboratories (ABT) traded lower by about 3% to 4% today. The stock slipped toward the mid-$120s, reflecting investor caution about the financial implications of a multibillion-dollar acquisition.
Historically, acquirers often face short-term pressure as markets assess deal size, funding structure, and potential dilution. Today’s pullback for Abbott mirrors that pattern.
Why the Market Is Reacting This Way
The contrasting moves highlight two different investor reactions:
-
EXAS investors see premium potential, strong growth prospects, and significant value in its cancer-testing pipeline.
-
ABT investors are assessing the cost, integration complexity, and regulatory scrutiny that accompany large healthcare acquisitions.
Still, analysts note that Abbott’s diagnostics division could become a powerhouse if the deal proceeds, given Exact Sciences’ leadership in cancer screening.
Deal Speculation Driving Sector Buzz
Industry insiders report that talks between the two companies have progressed, although no final agreement has been confirmed.
The potential acquisition would give Abbott access to Exact Sciences’ fast-growing portfolio, including Cologuard, Cologuard Plus, and new multi-cancer early detection technologies.
Exact Sciences has posted strong revenue growth throughout 2025, making it one of the most attractive targets in the diagnostics space.
Key Numbers Today (Thursday, Nov 19)
-
EXAS (Exact Sciences):
• Up nearly +19% intraday
• High: ~$88.89
• Low: ~$69.12
• Strong trading volume -
ABT (Abbott Laboratories):
• Down -3% to -4%
• Trading in the mid-$120s
• Heavy activity as investors digest takeover rumors
What Happens Next
Market watchers expect further updates soon. If talks continue without setbacks, a formal announcement could come in the near term. Until then, volatility is likely to persist for both stocks.
The Exact Sciences rally shows investors believe a premium-priced acquisition is increasingly likely.
For Abbott, the market remains cautious but recognizes the long-term strategic value of absorbing a fast-growing diagnostics leader.
Also Read
Nvidia’s ‘Make-or-Break’ Moment: How One Earnings Call Can Move the Entire Global Market
